-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2025-522169-31-00
4
2025-10-30
Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
-
2023-509629-36-00
9
2025-10-29
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
-
2024-512831-66-00
3
2025-10-24
Pediatric participants aged two to less than 18 years old with somatos
-
2025-520694-39-00
4
2025-10-24
Metastatic or locally advanced irresectable (stage IV) gastric cancer
-
2025-521916-20-00
1
2025-10-24
Cancer
-
2024-514912-28-00
10
2025-10-22
Patients with hepatocellular carcinoma with high tumor burden.
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2023-510558-18-00
4
2025-10-13
locally advanced head and neck squamous cell carcinoma
-
2025-521147-21-00
4
2025-10-08
Lung Cancer
-
2024-519188-17-00
1
2025-10-07
Relapsed/refractory malignancy with documented diagnosis of human epid
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-519445-29-00
1
2025-10-02
Solid Tumors
-
2024-520051-24-00
4
2025-09-30
Breast cancer
-
2024-512177-27-01
5
2025-09-29
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invas
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-513663-10-01
3
2025-09-17
Neoplasms
-
2024-517190-24-00
4
2025-09-16
Peritoneal Cancer
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-510943-76-00
5
2025-09-03
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
-
2024-516437-12-00
9
2025-08-29
Clear cell renal cell carcinoma